Navigation Links
Thoratec Announces Appointment of William A. Hawkins to Board of Directors
Date:12/16/2011

PLEASANTON, Calif., Dec. 16, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced the appointment of William A. Hawkins to its board of directors. 

"Bill brings tremendous skill, leadership, and experience to the Thoratec team, and we are delighted to add him to our board of directors," said Neil F. Dimick, Chairman of Thoratec's board of directors.  Gary F. Burbach, President and CEO, added, "Bill has been a leader in the healthcare industry for over three decades.  We are confident that his industry knowledge, strategic insight, and depth of experience, spanning from technology innovation to market development to broader healthcare policy, will be of great value to Thoratec."

Hawkins currently serves as President and Chief Executive Officer of Immucor, Inc. and as a Senior Advisor to TPG Capital.  Previously, he held a number of senior executive positions at Medtronic, Inc., including the role of Chairman and Chief Executive Officer.  Prior to Medtronic, Hawkins was the Chief Executive Officer of Novoste Corporation and held leadership positions at American Home Products, Eli Lilly, Johnson & Johnson, and Guidant.  Additionally, he has served on a number of corporate and non-profit boards of directors.

"I am excited to join the Thoratec board," said Mr. Hawkins.  "Thoratec has a rich history of innovation and leadership in the mechanical circulatory support industry, and I look forward to participating in the company's mission of driving greater adoption of its therapies, in order to deliver meaningful benefits to patients worldwide."

Mr. Hawkins's appointment will be effective as of January 1, 2012.  His appointment brings the number of the company's directors to nine
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Texas , Sept. 2, 2014  XBiotech ... III study being conducted in the US for ... True Human™ monoclonal antibody therapy, is being evaluated ... further complicated with cachexia. The primary endpoint of ... Xilonix treated patients to a control population provided ...
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... DIEGO, May 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Jefferies 2012 Global Healthcare Conference in New York on ... PT . Kurt Gustafson, Chief Financial Officer, Halozyme ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) The presentation will ...
... American Pharmacists Association (APhA), a DC-based, non-profit professional ... announced that on Monday evening, May 28, 2012, ... and defaced by an unknown individual or group.  ... APhA considers any attack on its ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 2
(Date:9/3/2014)... Job seekers who are interested in expanding their ... do both on iHire. By incorporating MOOCtracks into the ... investigating employment and educational opportunities in the same place. ... skills gaps and challenging the landscape of education by ... and mortar universities. To make it easier for their ...
(Date:9/3/2014)... Morris Psychological Group , ... for depression on October 9, 2014 from 4:30-8:30 ... than 1,000 organizations nationwide will be hosting National ... military installations. After completing a screening, participants will ... that can offer further evaluation and treatment if ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Joulebody, the ... 20 day custom healthy detox and weight-loss program ... Why?,     Because it’s good for ... clean-out their body. ,     Because using an elimination ... the countless testimonials of clients letting go of caffeine, ...
(Date:9/2/2014)... September 03, 2014 Autumn is ... wants to celebrate the new season with worldwide ... research and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), ... suppliers of 2014. , Since 2002 HostGator ... provider, and the company’s reputation for reliability remains ...
(Date:9/2/2014)... The symptoms of dry eye disease include the sensation ... burning and visual disturbance. The causes are poorly understood., ... aged 20 to 87 (average age 57) from the ... Thomas, Hospital in London., This cohort is widely regarded ... been used to look at a wide range of ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... at understanding the influences of paternity on the brain, ... of their close// resemblance with humans. Tiny monkeys called ... valuable insight into how fatherhood can actually ... found that there were structural changes in the brain ...
... increasing the time that kids spend in exercise will not ... weight. //Economist John Cawley of Cornell University and colleagues found ... of students taking part in physical education decreased from 42% ... examined data on 37,000 teens in grades nine through 12. ...
... first trimester could be associated with cardiac abnormalities in ... septal defects, Journal Birth Defects Research Part B, Trimester, ... who take non-steroidal anti-inflammatory drugs (NSAIDs) early in their ... babies with congenital defects. ,The findings of ...
... attention now a days experts have began to ponder as ... //for their own good. ,There are now a ... health groups, like the World Health Organization, the U.S. Centers ... Pediatrics as to if baby fat, which is usually a ...
... mosquito-borne encephalitis B in China, the Beijing News said on ... already killed by the disease. ,In central Henan ... and 40 of them have died so far. These infections ... months of 2006. But the newspaper did not explain why ...
... issue of the Journal, Vascular Surgery, researchers at the University ... put people younger than 60 more at risk of premature ... the study done on nearly 2,500 people younger than 60 ... ,Peripheral vascular disease is a narrowing of blood vessels ...
Cached Medicine News:Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Chubbiness In Babies Might Not Be A Cute Sign 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Similar in construction to the E2002 Utrata Capsulorhexis Forceps with jaw set to open only 3 mm. Flat handle with dull finish....
Medicine Products: